Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor

Kyu Jong Yoon, Nam Kyu Kim, Kang Young Lee, Byung Soh Min, Hyuk Hur, Jeonghyun Kang, Sarah Lee

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs have evolved significantly, and now IM is the standard care for patients with locally advanced, recurrent or metastatic GISTs. Adjuvant therapy with imatinib was recently approved for use, and preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. IM neoadjuvant therapy for primary GISTs has been reported, but there is no consensus on the dose of the drug, the duration of treatment and the optimal time of surgery. These are critical because drug resistance or tumor progression can develop with a prolonged treatment. This report describes two cases of large rectal malignant GISTs, for which a abdominoperineal resection was initially anticipated. The two patients received IM preoperative treatment; we followed-up with CT or magnetic resonance imaging to access the response. After 9 months of treatment, a multi-disciplinary consensus that maximal benefit from imatinib had been achieved was reached. We determined the best time for surgical intervention and successfully performed sphincter-preserving surgery before resistance to imatinib or tumor progression occurred. We believe that a multidisciplinary team approach, considerating the optimal duration of therapy and the timing of surgery, is required to optimize treatment outcome.

Original languageEnglish
Pages (from-to)147-152
Number of pages6
JournalJournal of the Korean Society of Coloproctology
Volume27
Issue number3
DOIs
Publication statusPublished - 2011 Jun 30

Fingerprint

Gastrointestinal Stromal Tumors
Neoadjuvant Therapy
Rectal Neoplasms
Therapeutics
Imatinib Mesylate
Drug Resistance
Neoplasms
Patient Care
Magnetic Resonance Imaging

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cite this

Yoon, Kyu Jong ; Kim, Nam Kyu ; Lee, Kang Young ; Min, Byung Soh ; Hur, Hyuk ; Kang, Jeonghyun ; Lee, Sarah. / Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor. In: Journal of the Korean Society of Coloproctology. 2011 ; Vol. 27, No. 3. pp. 147-152.
@article{8cc40fdc56584fcda96da0448f9b3965,
title = "Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor",
abstract = "Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs have evolved significantly, and now IM is the standard care for patients with locally advanced, recurrent or metastatic GISTs. Adjuvant therapy with imatinib was recently approved for use, and preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. IM neoadjuvant therapy for primary GISTs has been reported, but there is no consensus on the dose of the drug, the duration of treatment and the optimal time of surgery. These are critical because drug resistance or tumor progression can develop with a prolonged treatment. This report describes two cases of large rectal malignant GISTs, for which a abdominoperineal resection was initially anticipated. The two patients received IM preoperative treatment; we followed-up with CT or magnetic resonance imaging to access the response. After 9 months of treatment, a multi-disciplinary consensus that maximal benefit from imatinib had been achieved was reached. We determined the best time for surgical intervention and successfully performed sphincter-preserving surgery before resistance to imatinib or tumor progression occurred. We believe that a multidisciplinary team approach, considerating the optimal duration of therapy and the timing of surgery, is required to optimize treatment outcome.",
author = "Yoon, {Kyu Jong} and Kim, {Nam Kyu} and Lee, {Kang Young} and Min, {Byung Soh} and Hyuk Hur and Jeonghyun Kang and Sarah Lee",
year = "2011",
month = "6",
day = "30",
doi = "10.3393/jksc.2011.27.3.147",
language = "English",
volume = "27",
pages = "147--152",
journal = "Annals of Coloproctology",
issn = "2287-9714",
publisher = "Korean Society of Coloproctology",
number = "3",

}

Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor. / Yoon, Kyu Jong; Kim, Nam Kyu; Lee, Kang Young; Min, Byung Soh; Hur, Hyuk; Kang, Jeonghyun; Lee, Sarah.

In: Journal of the Korean Society of Coloproctology, Vol. 27, No. 3, 30.06.2011, p. 147-152.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of imatinib mesylate neoadjuvant treatment for a locally advanced rectal gastrointestinal stromal tumor

AU - Yoon, Kyu Jong

AU - Kim, Nam Kyu

AU - Lee, Kang Young

AU - Min, Byung Soh

AU - Hur, Hyuk

AU - Kang, Jeonghyun

AU - Lee, Sarah

PY - 2011/6/30

Y1 - 2011/6/30

N2 - Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs have evolved significantly, and now IM is the standard care for patients with locally advanced, recurrent or metastatic GISTs. Adjuvant therapy with imatinib was recently approved for use, and preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. IM neoadjuvant therapy for primary GISTs has been reported, but there is no consensus on the dose of the drug, the duration of treatment and the optimal time of surgery. These are critical because drug resistance or tumor progression can develop with a prolonged treatment. This report describes two cases of large rectal malignant GISTs, for which a abdominoperineal resection was initially anticipated. The two patients received IM preoperative treatment; we followed-up with CT or magnetic resonance imaging to access the response. After 9 months of treatment, a multi-disciplinary consensus that maximal benefit from imatinib had been achieved was reached. We determined the best time for surgical intervention and successfully performed sphincter-preserving surgery before resistance to imatinib or tumor progression occurred. We believe that a multidisciplinary team approach, considerating the optimal duration of therapy and the timing of surgery, is required to optimize treatment outcome.

AB - Surgery is the standard treatment for a primary gastrointestinal stromal tumor (GIST); however, surgical resection is often not curative, particularly for large GISTs. In the past decade, with imatinib mesylate (IM), management strategies for GISTs have evolved significantly, and now IM is the standard care for patients with locally advanced, recurrent or metastatic GISTs. Adjuvant therapy with imatinib was recently approved for use, and preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. IM neoadjuvant therapy for primary GISTs has been reported, but there is no consensus on the dose of the drug, the duration of treatment and the optimal time of surgery. These are critical because drug resistance or tumor progression can develop with a prolonged treatment. This report describes two cases of large rectal malignant GISTs, for which a abdominoperineal resection was initially anticipated. The two patients received IM preoperative treatment; we followed-up with CT or magnetic resonance imaging to access the response. After 9 months of treatment, a multi-disciplinary consensus that maximal benefit from imatinib had been achieved was reached. We determined the best time for surgical intervention and successfully performed sphincter-preserving surgery before resistance to imatinib or tumor progression occurred. We believe that a multidisciplinary team approach, considerating the optimal duration of therapy and the timing of surgery, is required to optimize treatment outcome.

UR - http://www.scopus.com/inward/record.url?scp=80051484022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051484022&partnerID=8YFLogxK

U2 - 10.3393/jksc.2011.27.3.147

DO - 10.3393/jksc.2011.27.3.147

M3 - Article

C2 - 21829770

AN - SCOPUS:80051484022

VL - 27

SP - 147

EP - 152

JO - Annals of Coloproctology

JF - Annals of Coloproctology

SN - 2287-9714

IS - 3

ER -